U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. About FDA
  3. Reports, Manuals, & Forms
  4. Reports
  5. Economic Impact Analyses of FDA Regulations
  6. Annual Summary Reporting Requirements Under the Right to Try Act (Proposed Rule) Regulatory Impact Analysis
  1. Economic Impact Analyses of FDA Regulations

Annual Summary Reporting Requirements Under the Right to Try Act (Proposed Rule) Regulatory Impact Analysis

To facilitate implementation of the reporting requirements of the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 (Right to Try Act), the Food and Drug Administration (FDA, the Agency) is proposing to establish requirements for the deadline and contents of submission of an annual summary. This proposed rule, if finalized, would implement the statutory requirement under provisions of the Right to Try Act for submission of an annual summary by sponsors and manufacturers who provide an eligible investigational drug for use by an eligible patient.

Annual Summary Reporting Requirements Under the Right to Try Act Document (PDF - 325KB)

Federal Register: 85 FR 44803, July 24, 2020

Docket: FDA-2019-N-5553

Back to Top